3 Stocks Driving The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 16,507 as of Monday, Aug. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,334 issues advancing vs. 1,665 declining with 161 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the industry include NPS Pharmaceuticals ( NPSP), up 5.5%, Biomarin Pharmaceutical ( BMRN), up 2.0%, Grifols ( GRFS), up 1.5%, Eli Lilly and ( LLY), up 0.8% and AbbVie ( ABBV), up 0.5%. On the negative front, top decliners within the industry include Herbalife ( HLF), down 4.2%, Endo International ( ENDP), down 2.4%, Jazz Pharmaceuticals ( JAZZ), down 2.2%, Teva Pharmaceutical Industries ( TEVA), down 1.7% and Perrigo ( PRGO), down 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $1.42 (1.1%) to $126.97 on heavy volume. Thus far, 3.5 million shares of Amgen exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $126.52-$129.30 after having opened the day at $129.00 as compared to the previous trading day's close of $125.55.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $96.4 billion and is part of the health care sector. Shares are up 10.1% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Amgen a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Celgene ( CELG) is up $0.65 (0.8%) to $87.30 on light volume. Thus far, 1.7 million shares of Celgene exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $86.72-$88.40 after having opened the day at $87.19 as compared to the previous trading day's close of $86.65.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $34.8 billion and is part of the health care sector. Shares are up 2.6% year-to-date as of the close of trading on Friday. Currently there are 16 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, robust revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Celgene Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.81 (0.9%) to $92.31 on average volume. Thus far, 5.3 million shares of Gilead exchanged hands as compared to its average daily volume of 11.4 million shares. The stock has ranged in price between $91.52-$92.89 after having opened the day at $92.00 as compared to the previous trading day's close of $91.50.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $140.6 billion and is part of the health care sector. Shares are up 21.8% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs